Learn About Lymphofollicular Hyperplasia

What is the definition of Lymphofollicular Hyperplasia?

Lymphofollicular hyperplasia is an increase in the number of cells found in lymph node. These follicles contain normal white blood cells called lymphocytes. Your body produces more lymphocytes to help prevent bacteria, viruses, and other types of germs from entering the bloodstream.

Save information for later
Sign Up
What are the alternative names for Lymphofollicular Hyperplasia?

Lymphadenopathy; Lymphofollicular hypertrophy

Lymphatic system
Who are the top Lymphofollicular Hyperplasia Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Lymphofollicular Hyperplasia Clinical Trials?
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma

Summary: This phase I trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in treating patients with relapsed or refractory T-cell non-Hodgkin lymphoma or Hodgkin lymphoma. CPI-613 may kill cancer cells by turning off their mitochondria, which are used by cancer cells to produce energy and are the building blocks needed to make more cancer cells. By sh...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Efficacy and Safety of Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies:a Single-center, Open, Single-arm Clinical Study.

Summary: The overall purpose of this study is to explore the safety and therapeutic effect of CD30-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Refractory/Relapsed lymphocyte malignancies.

What are the Latest Advances for Lymphofollicular Hyperplasia?
Noncontiguous multifocal Brucella spondylodiscitis with paravertebral abscess: a case report.
Management of malignant submandibular gland tumors: A 30-year experience from a single center.
Tired of the same old research?
Check Latest Advances
Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients.
Who are the sources who wrote this article ?

Published Date: September 01, 2021
Published By: Jatin M. Vyas, MD, PhD, Associate Professor in Medicine, Harvard Medical School; Associate in Medicine, Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Winter JN. Approach to the patient with lymphadenopathy and splenomegaly. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 159.